Type your tag names separated by a space and hit enter

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Abstract

OBJECTIVE

To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA).

METHODS

We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.

RESULTS

The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.

CONCLUSION

This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    University of Alabama at Birmingham.

    ,

    University of Alabama at Birmingham.

    ,

    University of Alabama at Birmingham.

    ,

    American University of Beirut, Beirut, Lebanon, and McMaster University, Hamilton, Ontario, Canada.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    ,

    Beth Israel Deaconess Medical Center, Boston, Massachusetts.

    ,

    University of Alabama at Birmingham.

    ,

    University of California, Los Angeles.

    ,

    Washington University School of Medicine, St. Louis, Missouri.

    ,

    University of California, San Diego.

    ,

    University of Nebraska Medical Center, Omaha.

    ,

    North Mississippi Medical Center, Tupelo.

    ,

    Healthy Motivation, Santa Barbara, California.

    ,

    Mayo Clinic, Rochester, Minnesota.

    ,

    University of Minnesota and Park Nicollet Clinic, St. Louis Park.

    ,

    NorthShore University Health System, Evanston, Illinois.

    ,

    Global Healthy Living Foundation, New York, New York.

    ,

    NorthShore University Health System, Evanston, Illinois.

    ,

    Duke University Medical Center, Durham, North Carolina.

    ,

    Rheumatology Consultants of Oregon, West Linn.

    ,

    American College of Rheumatology, Atlanta, Georgia.

    ,

    Tufts Medical Center, Boston, Massachusetts.

    Source

    Arthritis care & research 68:1 2016 Jan pg 1-25

    MeSH

    Antirheumatic Agents
    Arthritis, Rheumatoid
    Biological Products
    Consensus
    Evidence-Based Medicine
    Humans
    Patient Selection
    Rheumatology
    Risk Factors

    Pub Type(s)

    Journal Article
    Practice Guideline
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    26545825

    Citation

    Singh, Jasvinder A., et al. "2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis." Arthritis Care & Research, vol. 68, no. 1, 2016, pp. 1-25.
    Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25.
    Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., ... McAlindon, T. (2016). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research, 68(1), pp. 1-25. doi:10.1002/acr.22783.
    Singh JA, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25. PubMed PMID: 26545825.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. AU - Singh,Jasvinder A, AU - Saag,Kenneth G, AU - Bridges,S Louis,Jr AU - Akl,Elie A, AU - Bannuru,Raveendhara R, AU - Sullivan,Matthew C, AU - Vaysbrot,Elizaveta, AU - McNaughton,Christine, AU - Osani,Mikala, AU - Shmerling,Robert H, AU - Curtis,Jeffrey R, AU - Furst,Daniel E, AU - Parks,Deborah, AU - Kavanaugh,Arthur, AU - O'Dell,James, AU - King,Charles, AU - Leong,Amye, AU - Matteson,Eric L, AU - Schousboe,John T, AU - Drevlow,Barbara, AU - Ginsberg,Seth, AU - Grober,James, AU - St Clair,E William, AU - Tindall,Elizabeth, AU - Miller,Amy S, AU - McAlindon,Timothy, AU - ,, Y1 - 2015/11/06/ PY - 2015/03/19/received PY - 2015/10/14/accepted PY - 2015/11/8/entrez PY - 2015/11/8/pubmed PY - 2016/5/18/medline SP - 1 EP - 25 JF - Arthritis care & research JO - Arthritis Care Res (Hoboken) VL - 68 IS - 1 N2 - OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. RESULTS: The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. CONCLUSION: This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies. SN - 2151-4658 UR - https://www.unboundmedicine.com/medline/citation/26545825/full_citation L2 - https://doi.org/10.1002/acr.22783 DB - PRIME DP - Unbound Medicine ER -